The Clinicopathological and Prognostic Value of the Pretreatment Neutrophil-to-lymphocyte Ratio in Small Cell Lung Cancer: A Meta-analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Apr 3

PMID 32241019

Citations 19

Authors

Yan Lu

Jinwen Jiang

Chaoxiang Ren

Affiliations

Soon will be listed here.

Abstract

Although many scholars have recently studied the relationships between the pretreatment neutrophil-to-lymphocyte ratio (NLR) and prognosis in patients with small cell lung cancer (SCLC), the conclusions have been inconsistent. Accordingly, in this meta-analysis, we attempted to assess the clinicopathological and prognostic value of the pretreatment NLR in SCLC. Related literature was searched using PubMed, Embase, Cochrane Library, Web of Science, Chinese Biomedical Literature, China National Knowledge Infrastructure (CNKI), and Wanfang databases. Each eligible study was extracted, and a meta-analysis was performed using hazard ratios (HRs) and 95% confidence intervals (95% CIs) to assess the prognostic value of NLR. Evaluation of the clinicopathological significance of NLR in SCLC used odds ratios (ORs) and 95% confidence intervals (95% CIs). We included a total of 20 studies with 21 outcomes (5141 patients) in this meta-analysis. The results showed that high pretreatment NLR was closely related to poorer progression free survival (PFS) and overall survival (OS) (PFS, HR = 1.55, 95% CI = 1.27-1.88, P < 0.0001; I2 = 0%; OS, HR = 1.40, 95% CI = 1.26-1.55, P < 0.00001; I2 = 64%). In addition, pretreatment NLR was significantly associated with clinical stage of SCLC (OR = 2.14, 95% CI = 1.35-3.39, P = 0.001). Our meta-analysis showed that high levels of pretreatment NLR were significantly associated with a more serious clinical stage and poorer PFS and OS in SCLC.

Citing Articles

Peripheral Circulating Blood Cells Deviation Based on Tumor Inflammatory Microenvironment Activity in Resected Upstaged Lung Adenocarcinomas.

Bonis A, Lunardi F, Pagliarini G, Verzeletti V, Lione L, Busetto A J Clin Med. 2025; 13(24.

PMID: 39768520 PMC: 11676159. DOI: 10.3390/jcm13247597.

[Correlation Analysis between Neutrophil-to-lymphocyte Ratio  and the Risk of Malnutrition in Stage IV Primary Lung Cancer].

Xiao P, Pan H, Ma Q, Song L, Zhong D Zhongguo Fei Ai Za Zhi. 2024; 27(3):193-198.

PMID: 38590194 PMC: 11002189. DOI: 10.3779/j.issn.1009-3419.2024.106.06.

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.

Takeda T, Yamada T, Kunimatsu Y, Tanimura K, Morimoto K, Shiotsu S Cancers (Basel). 2023; 15(5).

PMID: 36900334 PMC: 10001399. DOI: 10.3390/cancers15051543.

Prognostic Impact of C-Reactive Protein-to-Lymphocyte Ratio in Non-small Cell Lung Cancer: A Propensity Score-Matching Analysis.

Nagano T, Kinoshita F, Hashinokuchi A, Matsudo K, Watanabe K, Takamori S Ann Surg Oncol. 2023; 30(6):3781-3788.

PMID: 36847957 DOI: 10.1245/s10434-023-13250-8.

Peripheral Neutrophil-to-Lymphocyte Ratio in Bronchiectasis: A Marker of Disease Severity.

Martinez-Garcia M, Olveira C, Giron R, Garcia-Clemente M, Maiz-Carro L, Sibila O Biomolecules. 2022; 12(10).

PMID: 36291608 PMC: 9599714. DOI: 10.3390/biom12101399.

References

Xie D, Marks R, Zhang M, Jiang G, Jatoi A, Garces Y . Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. J Thorac Oncol. 2015; 10(8):1213-20. DOI: 10.1097/JTO.0000000000000585. View

Zhao H, Ren D, Liu H, Chen J . Comparison and discussion of the treatment guidelines for small cell lung cancer. Thorac Cancer. 2018; 9(7):769-774. PMC: 6026606. DOI: 10.1111/1759-7714.12765. View

Dirican A, Bolat Kucukzeybek B, Alacacioglu A, Kucukzeybek Y, Erten C, Varol U . Do the derived neutrophil to lymphocyte ratio and the neutrophil to lymphocyte ratio predict prognosis in breast cancer?. Int J Clin Oncol. 2014; 20(1):70-81. DOI: 10.1007/s10147-014-0672-8. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Yu Y, Qian L, Cui J . Value of neutrophil-to-lymphocyte ratio for predicting lung cancer prognosis: A meta-analysis of 7,219 patients. Mol Clin Oncol. 2017; 7(3):498-506. PMC: 5547766. DOI: 10.3892/mco.2017.1342. View

Gu X, Tian T, Tian X, Zhang X . Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep. 2015; 5:12493. PMC: 4513342. DOI: 10.1038/srep12493. View

Wang D, Guo D, Shi F, Zhu Y, Li A, Kong L . The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer. Future Oncol. 2019; 15(29):3367-3379. DOI: 10.2217/fon-2019-0288. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Balkwill F, Mantovani A . Inflammation and cancer: back to Virchow?. Lancet. 2001; 357(9255):539-45. DOI: 10.1016/S0140-6736(00)04046-0. View

10.

Bonomi M, Patsias A, Posner M, Sikora A . The role of inflammation in head and neck cancer. Adv Exp Med Biol. 2014; 816:107-27. DOI: 10.1007/978-3-0348-0837-8_5. View

11.

Zintzaras E, Ioannidis J . Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2004; 28(2):123-37. DOI: 10.1002/gepi.20048. View

12.

Wang Z, Zhan P, Lv Y, Shen K, Wei Y, Liu H . Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. Transl Lung Cancer Res. 2019; 8(3):214-226. PMC: 6626865. DOI: 10.21037/tlcr.2019.06.10. View

13.

Travis W, Brambilla E, Burke A, Marx A, Nicholson A . Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol. 2015; 10(9):1240-1242. DOI: 10.1097/JTO.0000000000000663. View

14.

Deng M, Ma X, Liang X, Zhu C, Wang M . Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?. Oncotarget. 2017; 8(23):37200-37207. PMC: 5514902. DOI: 10.18632/oncotarget.16553. View

15.

Wang X, Jiang R, Li K . Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys. 2014; 69(3):633-40. DOI: 10.1007/s12013-014-9845-3. View

16.

Sodja E, Rijavec M, Koren A, Sadikov A, Korosec P, Cufer T . The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer. Radiol Oncol. 2016; 50(2):188-96. PMC: 4852967. DOI: 10.1515/raon-2015-0027. View

17.

Sakin A, Sahin S, Yasar N, Demir C, Arici S, Geredeli C . The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer. Oncol Res Treat. 2019; 42(10):506-515. DOI: 10.1159/000501595. View

18.

Lohinai Z, Bonanno L, Aksarin A, Pavan A, Megyesfalvi Z, Santa B . Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer. PeerJ. 2019; 7:e7232. PMC: 6673426. DOI: 10.7717/peerj.7232. View

19.

Duval S, Tweedie R . Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000; 56(2):455-63. DOI: 10.1111/j.0006-341x.2000.00455.x. View

20.

Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q . Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku J Exp Med. 2015; 236(4):297-304. DOI: 10.1620/tjem.236.297. View